ProQR Therapeutics (NASDAQ:PRQR) Receives $7.60 Consensus Target Price from Analysts

ProQR Therapeutics (NASDAQ:PRQR) has been given an average recommendation of “Buy” by the five research firms that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $7.60.

PRQR has been the topic of several research reports. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. JMP Securities reiterated a “market outperform” rating and set a $8.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Chardan Capital reiterated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th.

ProQR Therapeutics Stock Performance

PRQR opened at $2.62 on Monday. The firm’s 50-day simple moving average is $3.29 and its 200-day simple moving average is $2.50. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62. The firm has a market cap of $214.00 million, a price-to-earnings ratio of -8.19 and a beta of 0.30.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PRQR. Privium Fund Management B.V. raised its position in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after acquiring an additional 51,663 shares during the period. BNP Paribas Financial Markets raised its position in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares during the period. Finally, OneDigital Investment Advisors LLC raised its position in shares of ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares during the period. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).